Results 121 to 130 of about 3,264 (192)

Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin. [PDF]

Am J Trop Med Hyg
Zhang Y, Liu Y, Yi H.
europepmc   +1 more source

CD20+ T follicular helper-like cells drive antigen-specific autoimmunity in bullous pemphigoid. [PDF]

J Clin Invest
Fang H, Shen S, Li K, Cao T, Wang B, Miao H, Xue K, Bai Y, Li L, Li X, Qiao P, Zhang J, Qu H, Zhang C, Xiao C, Pang B, Fu M, Qiao H, Shao S, Dang E, Wang G.   +20 more
europepmc   +1 more source

Combination biologic therapy in bullous pemphigoid: two case reports and a focused review. [PDF]

Front Immunol
Kyriakou A, Tsaousi A, Minas C, Anagnostaki ME, Fantakis A, Meltzanidou P, Tsitlakidou A, Daponte AI, Lazaridou E, Patsatsi A.   +9 more
europepmc   +1 more source

Peristomal bullous pemphigoid: expanding the spectrum of localized presentations. [PDF]

An Bras Dermatol
Ramírez-Bravo F, Contreras CA, Marcet GH, Martínez IW, Urrutia MJ, Castro A.   +5 more
europepmc   +1 more source

Successful Treatment of Bullous Pemphigoid Complicated by Possible Infective Endocarditis With Dupilumab Monotherapy: A Case Report. [PDF]

J Dermatol
Kohri N, Shiraishi K, Ishikawa E, Tsuboi S, Yoshida S, Nishihara K, Yatsuzuka K, Muto J, Fujisawa Y.   +8 more
europepmc   +1 more source

Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature. [PDF]

Skin Health Dis
Soto-Canetti G, Navrazhina K, Talia J.
europepmc   +1 more source

Recurrent bullous eruptions predominantly involving previously treated breast cancer sites. [PDF]

JAAD Case Rep
Namba M, Kogawa K, Terada A, Matsuzaki Y, Rokunohe D, Murai T, Akasaka E.   +6 more
europepmc   +1 more source

Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study. [PDF]

J Inflamm Res
Cui S, Zhang B, Chen F, Liu Y, Zhang J, Jin H, Li L.   +6 more
europepmc   +1 more source

Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor). [PDF]

Front Immunol
Qin C, Yang C, Wang Y, Zou Y, Ding X.
europepmc   +1 more source

Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report. [PDF]

Front Med (Lausanne)
Hu Y, Xu LL, Li KH, Yu CS, Wang SB.
europepmc   +1 more source